Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B
This article was originally published in The Pink Sheet Daily
Executive Summary
Company also awaits August PDUFA date for the same indication in the United States.
You may also be interested in...
Bristol’s Baraclude Beats Hepsera In Two-year Trial
Potent rival Viread aims to shake up hepatitis B market.
Bristol’s Baraclude Beats Hepsera In Two-year Trial
Potent rival Viread aims to shake up hepatitis B market.
HIV Sales Fuel Gilead’s Robust First Quarter
Biotech firm boasts record sales, record revenues.